BMS buys start-up IFM for $300mm up front plus over $2bn in earn-outs
Bristol-Myers Squibb Co. paid $300mm up front for IFM Therapeutics, a private start-up aiming to treat diseases by targeting the innate immune system.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com